USARx offers multiple ways to purchase this medication. Choose the Best option for you!
Note: This document contains side effect information about velaglucerase alfa. Some of the dosage forms listed on this page may not apply to the brand name VPRIV.
Applies to velaglucerase alfa: intravenous powder for solution
Along with its needed effects, velaglucerase alfa (the active ingredient contained in VPRIV) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.
Check with your doctor or nurse immediately if any of the following side effects occur while taking velaglucerase alfa:
Some side effects of velaglucerase alfa may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:
Applies to velaglucerase alfa: intravenous powder for injection
The most common side effects were hypersensitivity/infusion-related reactions. The most serious side effects reported were hypersensitivity reactions.
The term "hypersensitivity reaction" included any event related to and occurring within up to 24 hours of drug infusion, including at least 1 case of anaphylaxis.
The most common symptoms of hypersensitivity reactions were headache, dizziness, hypotension, hypertension, nausea, fatigue/asthenia, and pyrexia; reactions were generally mild. In therapy-naive patients, onset was usually during the first 6 months of therapy and occurred less often over time.
Very common (10% or more): Hypersensitivity reaction (up to 52%)
Frequency not reported: Anaphylaxis, anaphylactoid reaction
Very common (10% or more): Headache (up to 35%), dizziness (up to 22%)
Frequency not reported: Paresthesia
Very common (10% or more): Pyrexia/increased body temperature (up to 22%), asthenia/fatigue (13%), infusion-related reaction
Common (1% to 10%): Flushing
Frequency not reported: Peripheral edema, influenza-like illness
Very common (10% or more): Abdominal pain (up to 19%)
Common (1% to 10%): Nausea, upper abdominal pain
Frequency not reported: Diarrhea, vomiting
Very common (10% or more): Back pain (up to 18%), knee joint pain (up to 15%), arthralgia, bone pain
Frequency not reported: Muscle spasm, myalgia, neck pain
Very common (10% or more): Prolonged activated partial thromboplastin time (up to 11%)
Common (1% to 10%): Tachycardia, hypertension, hypotension
Common (1% to 10%): Rash, urticaria
Frequency not reported: Allergic dermatitis, tinea versicolor, pruritus
Common (1% to 10%): IgG antibodies to velaglucerase alfa (the active ingredient contained in VPRIV) positive for neutralizing antibody
Frequency not reported: Influenza, nasopharyngitis, rhinitis, bronchitis, cough, epistaxis
Frequency not reported: Cystitis, urinary tract infection